Chiasma, Inc. (CHMA) EPS Estimated At $-0.31

Chiasma, Inc. (NASDAQ:CHMA) Logo

Analysts expect Chiasma, Inc. (NASDAQ:CHMA) to report $-0.31 EPS on March, 19.They anticipate $0.10 EPS change or 47.62 % from last quarter’s $-0.21 EPS. After having $-0.31 EPS previously, Chiasma, Inc.’s analysts see 0.00 % EPS growth. The stock increased 3.90% or $0.26 during the last trading session, reaching $6.93. About 303,215 shares traded or 223.18% up from the average. Chiasma, Inc. (NASDAQ:CHMA) has risen 206.45% since March 14, 2018 and is uptrending. It has outperformed by 202.08% the S&P500.

Chiasma, Inc. (NASDAQ:CHMA) Ratings Coverage

Among 2 analysts covering Chiasma (NASDAQ:CHMA), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Chiasma had 4 analyst reports since February 14, 2019 according to SRatingsIntel. The stock of Chiasma, Inc. (NASDAQ:CHMA) has “Buy” rating given on Tuesday, February 19 by Roth Capital. The firm earned “Buy” rating on Friday, March 8 by H.C. Wainwright.

Chiasma, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing oral forms of therapies using transient permeability enhancer technology platform. The company has market cap of $169.55 million. The firm offers octreotide capsules, which is in Phase III clinical trial for the treatment of acromegaly, a condition that results in the body's production of excess growth hormone under the MYCAPSSA name. It currently has negative earnings.

More notable recent Chiasma, Inc. (NASDAQ:CHMA) news were published by: Benzinga.com which released: “58 Biggest Movers From Yesterday – Benzinga” on March 07, 2019, also Globenewswire.com with their article: “Chiasma to Participate in Three Investor Conferences in March – GlobeNewswire” published on March 04, 2019, Benzinga.com published: “The Daily Biotech Pulse: Allergan’s Depression Drug Flunks Late-Stage Trial, Apellis Offering, ShockWave Medical IPO – Benzinga” on March 07, 2019. More interesting news about Chiasma, Inc. (NASDAQ:CHMA) were released by: Seekingalpha.com and their article: “Chiasma up 15% ahead of Q4 report – Seeking Alpha” published on March 05, 2019 as well as Globenewswire.com‘s news article titled: “Chiasma Announces Support for Rare Disease Day 2019 – GlobeNewswire” with publication date: February 28, 2019.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.